Detalhe da pesquisa
1.
Perioperative Nivolumab in Resectable Lung Cancer.
N Engl J Med
; 390(19): 1756-1769, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38749033
2.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
N Engl J Med
; 381(21): 2020-2031, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562796
3.
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(2): 198-211, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33476593
4.
A Rare Case of a Testicular Teratoma Associated with a Neuroendocrine Tumour.
Chirurgia (Bucur)
; 114(2): 300-306, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31060665
5.
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
J Immunother Cancer
; 12(2)2024 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38346853
6.
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
Eur J Cancer
; 183: 174-187, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36871487
7.
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
J Thorac Oncol
; 18(8): 1055-1069, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37146754
8.
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
J Thorac Oncol
; 17(2): 289-308, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34648948
9.
The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: results of a prospective observational study.
Lung Cancer
; 63(2): 271-6, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18565617
10.
Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study.
Lung Cancer Manag
; 8(3): LMT15, 2019 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31807143
11.
Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib.
J BUON
; 12 Suppl 1: S137-49, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17935272
12.
Adjuvant chemotherapy for radically resected non-small cell lung cancer: a retrospective analysis of 311 consecutively treated patients.
Lung Cancer
; 47(1): 93-101, 2005 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15603859
13.
[New trends in adjuvant chemotherapy for non-small-cell lung cancer]. / Actualitati privind chimioterapia adjuvanta în cancerul pulmonar non-microcelular.
Pneumologia
; 54(2): 89-93, 2005.
Artigo
em Ro
| MEDLINE | ID: mdl-16536008